Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

Affiliations

• ¹ Department of Medical Oncology, Gustave Roussy, Villejuif, France. Electronic address: Fanny.POMMERET@gustaveroussy.fr.
• ² Department of Medical Oncology, Gustave Roussy, Villejuif, France.
• ³ Department of Hematology, Gustave Roussy, Villejuif, France.
• ⁴ Department of Therapeutic Innovation and Early Trials, Gustave Roussy, Villejuif, France.
• ⁵ Department of Radiotherapy, Gustave Roussy, Villejuif, France.
• ⁶ Etablissement Français du Sang, La Plaine St-Denis, Saint-Denis, France; UMR RIGHT 1098 Inserm, Etablissement Français du Sang, Université de Franche-Comté, Besançon, France.
• ⁷ Virologie, Pitié-Salpêtrière, AP-HP, Sorbonne Université, Paris, France.
• ⁸ Inserm IPLESP, Sorbonne Université, Hôpital St Antoine, AP-HP, Paris, France.
• ⁹ Department of Medical Oncology, Gustave Roussy, Villejuif, France; Aix-Marseille University, CRCM, INSERM, CNRS, Marseille, France.
• ¹⁰ Virology, Gustave Roussy, Villejuif, France.